These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 1728748

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vaccination with gp160 in HIV.
    Seligman SJ.
    N Engl J Med; 1992 Jan 30; 326(5):347; author reply 348. PubMed ID: 1558566
    [No Abstract] [Full Text] [Related]

  • 4. AIDS vaccine boosts immunity in HIV patients.
    RN; 1991 Oct 30; 54(10):103. PubMed ID: 1925340
    [No Abstract] [Full Text] [Related]

  • 5. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991 Oct 30; 9(1):51. PubMed ID: 1742945
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Properties of an HIV 'vaccine'.
    Wahren B, Sandström E, Wigzell H.
    Nature; 1993 Apr 08; 362(6420):505; author reply 505-6. PubMed ID: 8464491
    [No Abstract] [Full Text] [Related]

  • 10. Human trials of AIDS vaccines: current status and future directions.
    Koff WC, Fauci AS.
    AIDS; 1989 Apr 08; 3 Suppl 1():S125-9. PubMed ID: 2558684
    [No Abstract] [Full Text] [Related]

  • 11. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA, Schwartz DH, Fabry JA, Lieberman J.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep 01; 10(1):27-35. PubMed ID: 7648281
    [Abstract] [Full Text] [Related]

  • 12. Positive response. Encouraging results in the search for an AIDS vaccine.
    Beardsley T.
    Sci Am; 1991 Aug 01; 265(2):26. PubMed ID: 1862329
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
    Barrett N, Eder G, Dorner F.
    Biotechnol Ther; 1991 Aug 01; 2(1-2):91-106. PubMed ID: 1845126
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
    Zunich KM, Lane HC, Davey RT, Falloon J, Polis M, Kovacs JA, Masur H.
    AIDS Res Hum Retroviruses; 1992 Aug 01; 8(8):1335. PubMed ID: 1466952
    [No Abstract] [Full Text] [Related]

  • 16. Trial results thwart HIV-vaccine hopes.
    McCarthy M.
    Lancet; 1996 Apr 27; 347(9009):1173. PubMed ID: 8609757
    [No Abstract] [Full Text] [Related]

  • 17. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH, Messer KG, Hu SL.
    J Clin Invest; 1994 Jan 27; 93(1):140-6. PubMed ID: 8282780
    [Abstract] [Full Text] [Related]

  • 18. Gp160 of commercial HIV western blots is not gp160env. Should criteria for seropositivity be revised?
    Fenouillet E, Blanes N, Gluckman JC.
    AIDS; 1991 Jun 27; 5(6):770. PubMed ID: 1883550
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Which gp160 vaccine?
    Moore J, Lewis GK, Robinson J.
    Nature; 1993 Feb 11; 361(6412):503. PubMed ID: 7679205
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.